Carboplatin + Paclitaxel (adult granulosa cell tumor, advanced/recurrent)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-CARBOPLATIN DRUG-PACLITAXEL |
|---|
| ID | REG-CARBOPLATIN-PACLITAXEL-GCT |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Notes
Carboplatin + paclitaxel is widely used as first-line chemotherapy for advanced/recurrent adult granulosa cell tumor (AGCT), extrapolated from ovarian cancer chemotherapy practice. No large randomized trial specific to GCT. BEP (bleomycin-etoposide-cisplatin) is an alternative (especially in younger patients or when platinum-taxane sensitivity unknown). Response rates ~50–70% in recurrent disease. Surgery remains primary modality; chemo is for advanced/inoperable or chemotherapy-sensitive recurrence. Hormone-directed therapy (leuprolide, letrozole) is active in hormone receptor-positive GCT, especially for maintenance.
Used By
Indication
IND-GRANULOSA-CELL-1L-CARBOPLATIN-PACLITAXEL- IND-GRANULOSA-CELL-1L-CARBOPLATIN-PACLITAXEL